Uganda Martyrs University Institutional Repository (UMU-IR)
    • Login
    View Item 
    •   UMU-IR Home
    • Research Articles
    • Mother Kevin Postgraduate Medical School
    • Journal Articles (Medical School)
    • View Item
    •   UMU-IR Home
    • Research Articles
    • Mother Kevin Postgraduate Medical School
    • Journal Articles (Medical School)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force

    Thumbnail
    View/Open
    Bahendeka_Article_Medicine_2018_Concesus.pdf (1.149Mb)
    Date
    2018
    Author
    Kalra, Sanjay
    Bahendeka, Silver
    Sahay, Rakesh
    Ghosh, Sujoy
    Md, Fariduddin
    Orab, Abbas
    Ramaiya, Kaushik
    Shammari, Sameer Al
    Shrestha, Dina
    Shaikh, Khalid
    Abhayaratna, Sachitha
    Shrestha K, Pradeep
    Mahalingam, Aravinthan
    Askheta, Mazen
    Rahim, Aly Ahmed A
    Eliana, Fatimah
    Shrestha, Hari K.
    Chaudhary, Sandeep
    Ngugi, Nancy
    Mbanya, Jean Claude
    Aye, Than Than
    Latt, Tint Swe
    Akanov, Zhanay A.
    Syed, Abbas Raza
    Tandon, Nikhil
    Unnikrishnan, A. G.
    Madhu, S. V.
    Jawa, Ali
    Chowdhury, Subhankar
    Bajaj, Sarita
    Das, Ashok Kumar
    Metadata
    Show full item record
    Abstract
    For decades, sulfonylureas(SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. Furthermore, individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects. The current guidelines, developed by experts from Africa, Asia, and the Middle East, promote the safe and smart use of SUs in combination with other glucose‑lowering drugs.
    URI
    http://hdl.handle.net/20.500.12280/3012
    Collections
    • Journal Articles (Medical School) [120]

    UMU-IR
    Contact Us | Send Feedback | Library | Library Catalogue
    Atmire NV
     

     

    Browse

    UMU-IRCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    UMU-IR
    Contact Us | Send Feedback | Library | Library Catalogue
    Atmire NV